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The pathogenesis of colitis-associated colorectal cancer is strongly influenced by immune cells, cytokines and other
immune mediators present in the inflamed colon. Current research has emerged that T helper cell associated cytokines
play a prominent role in tumor growth. In our recent manuscript we have revealed that the Th17 associated cytokine
IL-21 prominently influences tumor development and immunosurveillance of colitis-associated colorectal cancer.
Longstanding inflammatory bowel diseases
(IBD) such as ulcerative colitis (UC) and
Crohn disease (CD) have an increased risk
to develop colorectal cancer.
1 This asso-
ciation of IBD with colorectal cancer was
first described by Crohn et al. in 1925.
2
Chronic inflammation promotes carcino-
genesis by inducing gene mutations and
epigenetic alterations, alteration of the
expression of factors involved in carcino-
genesis (p53, APC, K-ras, Bcl-2, NFkB,
COX-2, DNA mismatch— or base-
excision repair proteins), releasing of
reactive oxygen and nitrogen species,
inhibiting apoptosis or stimulating angio-
genesis and cell proliferation. The role of
the immune system during the process of
cancer development is multifactorial and
complex. Whereas some immune cells are
able to elicit protumoral effects others
diminish tumor progression as part of the
antitumoral immune response. However,
this extensive network of tumor immune
responses is far from completely under-
stood. Among hematopoietic cells which
can regulate cancer pathogenesis T cells
play a prominent role. Thus, CD4
+ T cells
as well as CD8
+ T cells and regulatory
T cells can influence the tumor micro-
milieu. With this regard T cell subsets
especially Th17 cells seem to be a poten-
tial target for new immunotherapeutic
approaches to treat colitis-associated colo-
rectal cancer as these cells were shown to
have prominent functions in mucosal
immunity. Th17 cells are termed accord-
ing to their secretion of the cytokine IL-
17A and are a distinct proinflammatory
CD4 effector T-cell lineage.
3 Besides the
secretion of IL-17A Th17 cells secrete the
cytokines IL-17F, IL-21 and IL-22. The
secretion of these Th17 cell-associated
cytokines leads to the induction of
chemokines, matrix metalloproteinases as
well as antimicrobial peptides in the
surrounding tissue, leading to inflam-
mation and recruitment of neutrophils
and macrophages, but less is known about
the function of these cytokines in cancer
development.
Among Th17-associated cytokines
IL-21 seems to represent an interesting
target for immunotherapeutic approaches
as IL-21 is able to tip the balance between
Th1 and Th17 cells.
4 IL-21 is able to
impact both innate and adaptive immune
responses due to its ability to act on
multiple immune cells expressing the
IL-21 receptor like B cells, NK cells,
activated T cells, DCs, macrophages as
well as fibroblasts and epithelial cells.
Upon engagement of its receptor IL-21
signals through JAKs, STAT3 and ulti-
mately Bcl-6, Tcf7, Lef1, Blimp-1 and
c-Maf. Therewith IL-21 is able to influ-
ence the differentiation, cell fate, pro-
liferation and survival of diverse immune
cell subsets. As mentioned above IL-21
promotes the differentiation of Th17 cells
whereas it limits the development of Tregs
and effector CD8
+ T cells. It has been
shown that IL-21 is overexpressed in the
gut of patients with UC and CD com-
pared with healthy controls
5 but also in
tumors of UC-associated cancer.
6 In
mouse models of intestinal colitis it was
shown that IL-21 exaggerates intestinal
acute colitis and that IL-21 is expressed in
tumor-infiltrating lymphocytes in a colitis-
associated cancer model.
6
In our recent study our aim was to
investigate the function of IL-21 during
the development of colitis-associated
tumorigenesis and its importance in tumor
immunosurveillance.
7 We analyzed the
course of chronic colitis in IL-21 deficient
mice. Likewise to the acute colitis, we
observed a dampened inflammation asso-
ciated with intact colon architecture and
decreased proliferation of intestinal cells in
IL-21-deficient mice compared with wild-
type (WT) mice due to diminished levels
of IFNc and IL-17. Opposing to previous
results in the acute colitis, we found
no alterations in Tregs levels in IL-21-
deficient mice during chronic colitis.
8
Surprisingly, when we combined chronic
colitis with tumorigenesis, IL-21 deficient
mice showed a similar extent of inflam-
mation compared with wild-type mice but
less tumor burden. The tumors from
IL-21 deficient mice were also reduced in
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diameter. This effect was due to low
tumor cell proliferation and high tumor
cell apoptosis in IL-21-deficient mice.
The intestinal cytokine milieu of IL-21
deficient mice with colitis-associated colo-
rectal cancer showed a decrease in IL-17,
while IFNc is highly upregulated, which
in turn mediated the severe intestinal
inflammation. Simultaneously, the Th17
inducing cytokine IL-23 was elevated in
WT mice whereas the Th1 inducing
cytokine IL-12p70 was upregulated in
IL-21-deficient mice. Other protumoral
cytokines like IL-6 and IL-22 remain
unchanged in IL-21-deficient mice. This
cytokine switch from a Th17-dominated
cytokine milieu toward a Th1-dominated
one happens during the transition phase
from acute to chronic intestinal inflam-
mation and is based on epithelial-derived
factors that are stimulating antigen-
presenting cells to induce this specific
adaptive immune responses. In our
studies we could verify that the increased
IFNc levels are the reason for an
enhanced antitumor response mediated
by CD103
+CD8
+ cytotoxic cells specific
for tumor cells. These CD103
+CD8
+
T cells were elevated in IL-21-deficient
mice in the course of colitis-associated
tumorigenesis. Further these cells showed
an enhanced cytotoxic potential against
E-cadherin
high-expressing tumor cells. In a
similar subsequent study Stolfi et al.
additionally showed reduced infiltration
of alternatively activated macrophages,
myeloid derived suppressor cells and
reduced phosphorylation of STAT3 and
diminished levels of Bcl-XL in IL-21
deficient mice.
6
In conclusion, our results clearly eluci-
date that IL-21 has a prominent function
in tumor growth and immunosurveillance
of colitis-associated tumorigenesis. IL-21
controls the balance between Th17 and
Th1 cell subsets and therewith is necessary
for the homeostasis of a tumor-supportive
microenvironment characterized by exten-
sive inflitration of Th17 cells. In addition,
IL-21 controls the development of cyto-
toxic CD103
+CD8
+ T cells whose cyto-
toxic capacity is also diminished in the
presence of IL-21.
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Figure1. Schematic overview of the characteristics of an IL-21 deficient in comparison to an IL-21
rich tumor milieu.
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